Rezafungin for previously untreated invasive candidiasis


featured image

Rezafungin is in development for the treatment of adult patients with previously untreated invasive candidiasis. Invasive candidiasis is a severe form of a common fungal infection that would normally affect the skin, but in the invasive form, infects the patients’ blood (candidaemia) or organs (e.g., brain, lungs, and the circulatory system).

Interventions: Rezafungin (CD101)
Indications: Invasive candidasis
Therapeutic Areas: Haematology , Infectious Disease
Year: 2022

Rezafungin is in development for the treatment of adult patients with previously untreated invasive candidiasis. Invasive candidiasis is a severe form of a common fungal infection that would normally affect the skin, but in the invasive form, infects the patients’ blood (candidaemia) or organs (e.g., brain, lungs, and the circulatory system). This is most common in patients who have other serious medical conditions which means their immune system can’t fight off the infection before it spreads around the body. Hospitalised patients, particularly those in intensive care are especially susceptible to invasive candidiasis infection.